Fig. 3From: Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agentsThe timeline of multi-targeted drugs with their FDA approval history. Chronic myeloid leukemia (CML), renal cell carcinoma (RCC), gastrointestinal tumors (GISTs), hepatocellular carcinoma (HCC), medullary thyroid cancer (MTC), non-small cell lung cancer (NSCLC).Back to article page